Opportunity Scan

Diamonds in the Rough

Cross-referencing fundamental value against technical exhaustion to isolate beaten-down XBI constituents that screen cheap and oversold. The bottom-right quadrant — high earnings yield, low RSI — is the prime hunting ground, especially where money flow (MFI) shows quiet accumulation despite the falling price.

50 in diamond zone152 scored

Educational screen, not investment advice. “Diamond” classification is a mechanical valuation-vs-RSI split around the cohort median earnings yield and an RSI of 50.

Alpha Quadrant — Valuation × Technical Exhaustion

X = earnings yield (cheaper right) · Y = RSI 14 (more oversold lower) · bubble = market cap · color = money flow.

Accumulation (MFI ≥ 55)Neutral flowDistribution (MFI ≤ 45)Diamond-zone ring

◆ Diamond in the RoughCheap + oversold. Deep value in a technically exhausted state — the prime target.

Fairly Valued WinnerCheap + extended. Strong action backed by earnings, but late for new entries.

Value TrapExpensive + beaten down. Falling yet still richly valued — structurally suspect.

Momentum DarlingExpensive + extended. Crowded leaders with mean-reversion risk.

Diamond Candidates

Ranked by a composite of earnings yield, ROIC, oversold RSI, recent weakness, and improving money flow.

#
1	IRWD	Ironwood Pharmaceuticals, Inc. - Class A	78.9	26.14%	1.38	37	-18.20%	50	distress
2	ABUS	Arbutus Biopharma Corporation Common Stock	67.7	18.22%	0.55	38	-13.40%	26	safe
3	INCY	Incyte Genomics Inc	56.5	9.00%	0.33	48	-7.28%	53	safe
4	RIGL	Rigel Pharmaceuticals Inc. (New)	56.4	9.77%	0.97	53	+0.54%	68	safe
5	EXEL	Exelixis Inc	50.4	6.11%	0.99	71	+13.81%	66	safe
6	ADMA	ADMA Biologics, Inc.	49.2	8.61%	0.42	58	+10.44%	67	safe
7	NRIX	Nurix Therapeutics, Inc. Common stock	47.9	14.02%	0.29	58	+6.65%	75	safe
8	ALNY	Alnylam Pharmaceuticals, Inc.	45.1	3.36%	0.27	42	-9.12%	51	safe
9	ACAD	Acadia Pharmaceuticals Inc.	45.0	2.77%	0.10	36	-19.07%	48	safe
10	NBIX	Neurocrine Biosciences Inc	41.2	5.38%	0.90	50	+3.00%	40	safe
11	MDXG	MiMedx Group, Inc	40.1	1.92%	0.05	30	-18.71%	22	safe
12	HALO	Halozyme Therapeutics, Inc.	39.6	4.01%	0.96	74	+12.04%	71	safe
13	KRYS	Krystal Biotech, Inc. Common Stock	38.9	2.19%	0.18	38	-8.88%	37	safe
14	UTHR	United Therapeutics Corp	38.3	6.02%	0.29	69	+24.28%	56	safe
15	QURE	uniQure N.V.	37.7	-15.25%	-0.25	28	-47.12%	60	distress

Short-Squeeze Watch

Constituents with the highest composite squeeze score — heavy short interest meeting price support.

#
1	AVBP	ArriVent BioPharma, Inc. Common Stock	91.9	25.21%	11.25	-29.86%	critical
2	RLAY	Relay Therapeutics, Inc. Common Stock	87.4	29.66%	12.59	+0.50%	critical
3	CRVS	Corvus Pharmaceuticals, Inc.	87.1	25.30%	13.31	-15.49%	critical
4	ZBIO	Zenas BioPharma, Inc. Common Stock	86.8	38.32%	15.48	-8.95%	critical
5	INBX	Inhibrx Biosciences, Inc. Common Stock	86.4	35.62%	11.82	-8.79%	critical
6	TYRA	Tyra Biosciences, Inc. Common Stock	86.4	26.23%	8.83	-11.74%	critical
7	SPRY	ARS Pharmaceuticals, Inc. Common Stock	85.9	43.26%	16.10	-4.28%	critical
8	IBRX	ImmunityBio, Inc. Common Stock	85.6	31.42%	8.88	-3.29%	critical
9	CELC	Celcuity Inc. Common Stock	85.6	27.57%	11.03	-18.16%	critical
10	ORIC	Oric Pharmaceuticals, Inc. Common Stock	84.1	27.01%	9.85	-0.38%	critical
11	SLS	SELLAS Life Sciences Group, Inc. Common Stock	83.9	27.66%	9.45	+0.96%	critical
12	IMVT	Immunovant, Inc. Common Stock	83.5	20.10%	9.64	-16.95%	critical

Market cap, valuation, and short-interest metrics are joined to the latest XBI holdings snapshot; each ticker links to its full quote and analysis page.